Mesoblast Limited submits Form 6-K with attached ASX press release

Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026.

Rhea-AI Filing Summary

Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 2, 2026, it filed a news release announcement with the Australian Securities Exchange, which is attached to this report as Exhibit 99.1 and incorporated by reference.

The filing is signed on behalf of Mesoblast by Company Secretary Paul Hughes and primarily serves to make the same press release available to U.S. investors through the SEC system.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mesoblast Limited (MEOBF) report in this Form 6-K?

The Form 6-K states that Mesoblast filed a news release announcement with the Australian Securities Exchange on January 2, 2026, and attaches that release as Exhibit 99.1.

Who signed this Mesoblast (MEOBF) Form 6-K?

The report was signed on behalf of Mesoblast Limited by Paul Hughes, the Company Secretary.

What is included as Exhibit 99.1 in Mesoblast’s January 2026 Form 6-K?

Exhibit 99.1 is described as a press release of Mesoblast Ltd, dated January 2, 2026.

Why did Mesoblast (MEOBF) file this Form 6-K?

Mesoblast used this Form 6-K to provide U.S. investors with the same January 2, 2026 press release that it filed with the Australian Securities Exchange.

What type of annual report does Mesoblast Limited file with the SEC?

The Form 6-K indicates that Mesoblast files its annual reports under cover of Form 20-F.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/02/2026 - 06:21 AM EST Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On January 2, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Paul Hughes

Paul Hughes

Company Secretary

Dated: January 2, 2026

INDEX TO EXHIBITS

Item
99.1						Press release of Mesoblast Ltd, dated January 2, 2026.